Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AORT Stock Forecast 2025-2026
$23.84
Current Price
$1.02B
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AORT Price Targets
+46.8%
To High Target of $35.00
+34.2%
To Median Target of $32.00
+25.8%
To Low Target of $30.00
AORT Price Momentum
+5.8%
1 Week Change
-1.7%
1 Month Change
+15.9%
1 Year Change
-16.6%
Year-to-Date Change
-26.3%
From 52W High of $32.33
+23.1%
From 52W Low of $19.36
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Artivion (AORT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AORT and similar high-potential opportunities.
Latest AORT Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, AORT has a bullish consensus with a median price target of $32.00 (ranging from $30.00 to $35.00). Currently trading at $23.84, the median forecast implies a 34.2% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Rick Wise at Stifel, suggesting a 25.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AORT Analyst Ratings
6
Buy
0
Hold
0
Sell
AORT Price Target Range
Low
$30.00
Average
$32.00
High
$35.00
Current: $23.84
Latest AORT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AORT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 25, 2025 | Needham | Mike Matson | Buy | Maintains | $32.00 |
| Feb 25, 2025 | Stifel | Rick Wise | Buy | Maintains | $30.00 |
| Feb 25, 2025 | Citizens Capital Markets | Daniel Stauder | Market Outperform | Reiterates | $33.00 |
| Jan 28, 2025 | Needham | Mike Matson | Buy | Reiterates | $34.00 |
| Dec 10, 2024 | JMP Securities | Daniel Stauder | Market Outperform | Reiterates | $33.00 |
| Dec 9, 2024 | Needham | Mike Matson | Buy | Reiterates | $34.00 |
| Nov 8, 2024 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $32.00 |
| Oct 23, 2024 | JMP Securities | Daniel Stauder | Market Outperform | Initiates | $33.00 |
| Sep 27, 2024 | Needham | Mike Matson | Buy | Reiterates | $30.00 |
| Sep 13, 2024 | Stifel | Rick Wise | Buy | Maintains | $30.00 |
| Aug 9, 2024 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $30.00 |
| Aug 9, 2024 | Stifel | Rick Wise | Buy | Maintains | $28.00 |
| Aug 9, 2024 | Needham | Mike Matson | Buy | Reiterates | $30.00 |
| Jul 2, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $30.00 |
| May 7, 2024 | Stifel | Rick Wise | Buy | Maintains | $25.00 |
| May 7, 2024 | Needham | Mike Matson | Buy | Maintains | $30.00 |
| Apr 8, 2024 | Needham | Mike Matson | Buy | Maintains | $25.00 |
| Feb 16, 2024 | Needham | Mike Matson | Buy | Maintains | $25.00 |
| Feb 16, 2024 | Stifel | Rick Wise | Buy | Maintains | $22.00 |
| Dec 7, 2023 | Needham | Mike Matson | Buy | Reiterates | $22.00 |
Artivion Inc. (AORT) Competitors
The following stocks are similar to Artivion based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Artivion Inc. (AORT) Financial Data
Artivion Inc. has a market capitalization of $1.02B with a P/E ratio of 0.0x. The company generates $388.54M in trailing twelve-month revenue with a -3.4% profit margin.
Revenue growth is +3.9% quarter-over-quarter, while maintaining an operating margin of +4.0% and return on equity of -4.8%.
Valuation Metrics
Market Cap
$1.02B
Enterprise Value
$1.31B
P/E Ratio
0.0x
PEG Ratio
99.3x
Price/Sales
2.6x
Growth & Margins
Revenue Growth (YoY)
+3.9%
Gross Margin
+63.2%
Operating Margin
+4.0%
Net Margin
-3.4%
EPS Growth
+3.9%
Financial Health
Cash/Price Ratio
+5.3%
Current Ratio
4.3x
Debt/Equity
131.2x
ROE
-4.8%
ROA
+2.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Artivion Inc. (AORT) Business Model
About Artivion Inc.
What They Do
Develops innovative medical devices for cardiac surgery.
Business Model
The company generates revenue by designing, manufacturing, and selling advanced medical devices specifically for cardiac and vascular procedures, focusing on areas like cryopreservation and heart valve therapies. Their products support healthcare professionals in performing complex surgical operations, which are critical for improving patient outcomes.
Additional Information
Artivion Inc. operates in a global market, emphasizing innovation and quality in its offerings. The company is headquartered in the United States and plays a significant role in enhancing surgical efficiency and effectiveness in the treatment of complex heart conditions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,600
CEO
Mr. James Patrick Mackin
Country
United States
IPO Year
1993
Website
artivion.comArtivion Inc. (AORT) Latest News & Analysis
Latest News
Quick Summary
Artivion, Inc. (NYSE: AORT) will release Q1 2025 financial results on May 5, 2025, after market close, followed by a teleconference at 4:30 p.m. ET.
Why It Matters
The upcoming financial results and teleconference for Artivion, Inc. could influence stock performance and investor sentiment, impacting trading decisions and market valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Artivion (AORT) experienced significant trading volume recently. However, recent earnings estimate revisions may indicate challenges for the stock's upward momentum.
Why It Matters
Artivion's increased trading volume signals heightened investor interest, but negative earnings estimate revisions could indicate potential short-term weakness in the stock.
Source: Zacks Investment Research
Market Sentiment:
Positive
Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
1 month ago
Quick Summary
Artivion, Inc. (NYSE: AORT) will participate virtually in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference on March 4, 2025, at 10:40 a.m.
Why It Matters
Artivion's participation in a major healthcare conference highlights its market presence and growth potential, potentially influencing investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Artivion (AORT) is now considered technically oversold, suggesting reduced selling pressure. Analysts are also revising earnings estimates upward, indicating a potential trend reversal.
Why It Matters
Artivion's oversold status signals diminished selling pressure, while upgraded earnings estimates suggest a potential rebound, indicating a buying opportunity for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Artivion, Inc. will hold its Q4 2024 earnings conference call on February 24, 2025, at 4:30 PM ET, featuring executives and analysts from various investment firms.
Why It Matters
The upcoming Q4 2024 earnings call for Artivion will provide insights into financial performance and future guidance, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
In Q4 2024, revenue rose 4% to $97.3M; full-year revenue increased 10% to $388.5M. Net loss narrowed to $(16.5)M. Adjusted EBITDA grew 15% to $17.6M in Q4.
Why It Matters
Revenue growth signals improving company performance, while reduced net losses suggest better financial health. Adjusted EBITDA increase indicates operational efficiency, appealing to potential investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AORT Stock
What is Artivion Inc.'s (AORT) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Artivion Inc. (AORT) has a median price target of $32.00. The highest price target is $35.00 and the lowest is $30.00.
Is AORT stock a good investment in 2025?
According to current analyst ratings, AORT has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $23.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AORT stock?
Wall Street analysts predict AORT stock could reach $32.00 in the next 12 months. This represents a 34.2% increase from the current price of $23.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Artivion Inc.'s business model?
The company generates revenue by designing, manufacturing, and selling advanced medical devices specifically for cardiac and vascular procedures, focusing on areas like cryopreservation and heart valve therapies. Their products support healthcare professionals in performing complex surgical operations, which are critical for improving patient outcomes.
What is the highest forecasted price for AORT Artivion Inc.?
The highest price target for AORT is $35.00 from at , which represents a 46.8% increase from the current price of $23.84.
What is the lowest forecasted price for AORT Artivion Inc.?
The lowest price target for AORT is $30.00 from Rick Wise at Stifel, which represents a 25.8% increase from the current price of $23.84.
What is the overall AORT consensus from analysts for Artivion Inc.?
The overall analyst consensus for AORT is bullish. Out of 7 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $32.00.
How accurate are AORT stock price projections?
Stock price projections, including those for Artivion Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 10:08 AM UTC